Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Endpoint Selection Could Help Determine The NASH Race

Nov 21 2016

• By Joseph Haas

Related Content

With Phase III NASH Endpoints In Place, Intercept May Reach Market By 2018

May 19 2015

NASH Race No More Clear After AASLD Than Before

Nov 30 2015

Intercept’s Phase III Endpoints May Not Apply To Other Firms’ NASH Programs

May 25 2015

Galectin Hopes To Set Surrogate Endpoints For NASH Cirrhosis, Despite Trial Failure

Sep 28 2016

Intercept Thinks Fibrosis Effect Could Carry Its NASH Candidate

Nov 17 2014

Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

Jul 25 2016

Intercept rollercoaster continues with NASH, PBC updates

Nov 10 2014

Combination Strategies A Common Thread In NASH R&D

Nov 21 2016

Intercept Seeks Long-Term Data To Build <em>Ocaliva</em> Market In PBC

Nov 16 2016

Searching For Surrogate Endpoints Requires Teamwork

Sep 30 2013

Related Companies

Intercept Pharmaceuticals, Inc.

Genfit SA

Allergan plc

Allergan plc

Novartis AG

Sumitomo Pharma Co., Ltd.

Galectin Therapeutics Inc.

Additional Topics

Clinical Trials Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window